Biohaven [BHVN] vs Dyne Therapeutics [DYN] Detailed Stock Comparison
Biohaven
NYSE
Loading...
Dyne Therapeutics
NASDAQ
Loading...
TLDR: Quick Comparison Summary
Based on 15 vital metrics comparison: Biohaven wins in 1 metrics, Dyne Therapeutics wins in 11 metrics, with 3 ties. Dyne Therapeutics appears stronger overall.
View Metrics Details
Vital Metrics Comparison
| Metric | Biohaven | Dyne Therapeutics | Better |
|---|---|---|---|
| P/E Ratio (TTM) | -1.70 | -3.88 | Dyne Therapeutics |
| Price-to-Book Ratio | 12.43 | 2.61 | Dyne Therapeutics |
| Debt-to-Equity Ratio | 25.63 | 21.19 | Dyne Therapeutics |
| PEG Ratio | 0.04 | -0.10 | Dyne Therapeutics |
| EV/EBITDA | -1.40 | -2.95 | Dyne Therapeutics |
| Profit Margin (TTM) | 0.00% | 0.00% | Tie |
| Operating Margin (TTM) | 0.00% | 0.00% | Tie |
| Return on Equity | -295.94% | -61.32% | Dyne Therapeutics |
| Return on Assets (TTM) | -103.41% | -35.45% | Dyne Therapeutics |
| Free Cash Flow (TTM) | $-586.50M | $-294.75M | Dyne Therapeutics |
| 1-Year Return | -66.81% | -59.91% | Dyne Therapeutics |
| Enterprise Value | $1.30B | $1.30B | Biohaven |
| Revenue per Share (TTM) | $0 | $0 | Tie |
| Earnings per Share (Diluted) | $-7.46 | $-3.88 | Dyne Therapeutics |
| Beta (Stock Volatility) | 3.45 | 1.08 | Dyne Therapeutics |
Performance
News Sentiment
Key Stats
Valuation
Financials
Short Interest
Dividends
Biohaven vs Dyne Therapeutics Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| Biohaven | 1.93% | 5.40% | -2.47% | 8.07% | -23.07% | -57.59% |
| Dyne Therapeutics | 4.06% | -0.68% | -3.12% | 49.09% | 38.64% | -48.70% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Biohaven | -66.81% | 22.65% | 116.58% | -11.73% | -11.73% | -11.73% |
| Dyne Therapeutics | -59.91% | 2.67% | -29.94% | -42.72% | -42.72% | -42.72% |
News Based Sentiment: Biohaven vs Dyne Therapeutics
Biohaven
News based Sentiment: POSITIVE
The month of October 2025 brought continued positive signals for Biohaven Ltd. (BHVN), with analysts reaffirming a "Strong Buy" rating and a substantial price target upside. While the share price increase was modest, the overall sentiment suggests a favorable investment outlook.
Dyne Therapeutics
News based Sentiment: POSITIVE
October was a strong month for Dyne Therapeutics, highlighted by key regulatory approvals (FDA Breakthrough Therapy and Japanese Orphan Drug designation) for DYNE-251, coupled with positive analyst upgrades and insider buying activity. While the company remains pre-revenue, these developments signal significant progress and potential for future growth, making it a noteworthy investment story.
Performance & Financial Health Analysis: Biohaven vs Dyne Therapeutics
| Metric | BHVN | DYN |
|---|---|---|
| Market Information | ||
| Market Cap | $1.69B | $1.95B |
| Market Cap Category | Small cap | Small cap |
| 10 Day Avg. Volume | 2,276,949 | 2,426,520 |
| 90 Day Avg. Volume | 2,397,840 | 2,473,740 |
| Last Close | $15.81 | $13.06 |
| 52 Week Range | $12.79 - $55.70 | $6.36 - $35.90 |
| % from 52W High | -71.62% | -63.62% |
| All-Time High | $67.86 (Jun 03, 2019) | $47.45 (Aug 19, 2024) |
| % from All-Time High | -76.70% | -72.48% |
| Growth Metrics | ||
| Quarterly Revenue Growth | N/A | N/A |
| Quarterly Earnings Growth | N/A | N/A |
| Financial Health | ||
| Profit Margin (TTM) | 0.00% | 0.00% |
| Operating Margin (TTM) | 0.00% | 0.00% |
| Return on Equity (TTM) | -2.96% | -0.61% |
| Debt to Equity (MRQ) | 25.63 | 21.19 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | $1.27 | $5.00 |
| Cash per Share (MRQ) | $3.83 | $4.81 |
| Operating Cash Flow (TTM) | $-645,078,016 | $-359,560,000 |
| Levered Free Cash Flow (TTM) | $-508,353,632 | $-222,398,000 |
| Dividends | ||
| Last 12-Month Dividend Yield | N/A | N/A |
| Last 12-Month Dividend | N/A | N/A |
Valuation & Enterprise Metrics Analysis: Biohaven vs Dyne Therapeutics
| Metric | BHVN | DYN |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | -1.70 | -3.88 |
| Forward P/E | -2.50 | -4.13 |
| PEG Ratio | 0.04 | -0.10 |
| Price to Sales (TTM) | N/A | N/A |
| Price to Book (MRQ) | 12.43 | 2.61 |
| Market Capitalization | ||
| Market Capitalization | $1.69B | $1.95B |
| Enterprise Value | $1.30B | $1.30B |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | N/A | N/A |
| Enterprise to EBITDA | -1.40 | -2.95 |
| Risk & Other Metrics | ||
| Beta | 3.45 | 1.08 |
| Book Value per Share (MRQ) | $1.27 | $5.00 |
Financial Statements Comparison: Biohaven vs Dyne Therapeutics
Financial Metrics
Loading Financial Charts...
Revenue
EBITDA
Operating Margin
Free Cash Flow
Long Term Debt
Profit Margin
Current Ratio
Operating Cash Flow
Income Statement (MRQ)
| Metric (MRQ) | BHVN | DYN |
|---|---|---|
| Revenue/Sales | $0 | $0 |
| Cost of Goods Sold | N/A | N/A |
| Gross Profit | N/A | N/A |
| Research & Development | $187.58M | $99.24M |
| Operating Income (EBIT) | $-221.56M | $-115.79M |
| EBITDA | $-219.32M | $-110.26M |
| Pre-Tax Income | $-221.07M | $-110.86M |
| Income Tax | $609,000 | N/A |
| Net Income (Profit) | $-221.68M | $-110.86M |
Balance Sheet & Liquidity Metrics (MRQ)
| Metric (MRQ) | BHVN | DYN |
|---|---|---|
| Cash & Equivalents | $98.42M | $472.26M |
| Total Current Assets | $382.76M | $689.50M |
| Total Current Liabilities | $164.03M | $33.88M |
| Long-Term Debt | $30.80M | $18.22M |
| Total Shareholders Equity | $259.50M | $668.97M |
| Retained Earnings | $-1.57B | $-1.07B |
| Property, Plant & Equipment | $36.78M | $34.19M |
Cash Flow Statement Comparison (MRQ)
| Metric (MRQ) | BHVN | DYN |
|---|---|---|
| Operating Cash Flow | $-164.28M | $-110.37M |
| Capital Expenditures | $-461,000 | $-981,000 |
| Free Cash Flow | $-165.59M | $-106.87M |
| Debt Repayment | N/A | N/A |
| Common Stock Repurchase | N/A | N/A |
Short Interest & Institutional Ownership Analysis
| Metric | BHVN | DYN |
|---|---|---|
| Shares Short | 13.19M | 15.30M |
| Short Ratio | 6.20 | 6.78 |
| Short % of Float | 0.14% | 0.12% |
| Average Daily Volume (10 Day) | 2,276,949 | 2,426,520 |
| Average Daily Volume (90 Day) | 2,397,840 | 2,473,740 |
| Shares Outstanding | 101.22M | 102.32M |
| Float Shares | 88.38M | 122.63M |
| % Held by Insiders | 0.12% | 0.00% |
| % Held by Institutions | 0.83% | 0.95% |
Dividend Analysis & Yield Comparison: Biohaven vs Dyne Therapeutics
| Metric | BHVN | DYN |
|---|---|---|
| Last 12-Month Dividend | N/A | N/A |
| Last 12-Month Dividend Yield | N/A | N/A |
| 3-Year Avg Annual Dividend | N/A | N/A |
| 3-Year Avg Dividend Yield | N/A | N/A |
| 3-Year Total Dividends | N/A | N/A |
| Ex-Dividend Date | N/A | N/A |